drugset / Trial / NCT00288379

SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma

NCT00288379 ↗

Phase 3 Completed 16 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose allergen challenge in allergic patients with mild asthma

Timeline

Start
2004-10
Primary completion
—
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 4.5 ug —
Subject budesonide/formoterol Unknown — —

Indications